41.58 USD
+0.09 (+0.22%)
41.58 USD
0 (0%)
KNSA gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 535 industry peers in the Biotechnology industry. While KNSA has a great health rating, its profitability is only average at the moment. An interesting combination arises when we look at growth and value: KNSA is growing strongly while it also seems undervalued. With these ratings, KNSA could be worth investigating further for value and growth investing!.
1. Profitability
1.1 Basic Checks
KNSA had positive earnings in the past year.
KNSA had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: KNSA reported negative net income in multiple years.
In multiple years KNSA reported negative operating cash flow during the last 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 5.04%, KNSA belongs to the top of the industry, outperforming 91.56% of the companies in the same industry.
Looking at the Return On Equity, with a value of 6.71%, KNSA belongs to the top of the industry, outperforming 91.93% of the companies in the same industry.
KNSA's Return On Invested Capital of 5.12% is amongst the best of the industry. KNSA outperforms 92.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.04% | ||
| ROE | 6.71% | ||
| ROIC | 5.12% |
ROA(3y)11.71%
ROA(5y)-15.78%
ROE(3y)13.22%
ROE(5y)-19.49%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 6.01%, KNSA belongs to the top of the industry, outperforming 90.99% of the companies in the same industry.
KNSA has a better Operating Margin (6.38%) than 90.24% of its industry peers.
KNSA has a better Gross Margin (87.52%) than 89.31% of its industry peers.
In the last couple of years the Gross Margin of KNSA has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.38% | ||
| PM (TTM) | 6.01% | ||
| GM | 87.52% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.87%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so KNSA is destroying value.
The number of shares outstanding for KNSA has been increased compared to 1 year ago.
Compared to 5 years ago, KNSA has more shares outstanding
KNSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 11.10 indicates that KNSA is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 11.10, KNSA belongs to the top of the industry, outperforming 84.99% of the companies in the same industry.
KNSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 11.1 |
ROIC/WACC0.55
WACC9.33%
2.3 Liquidity
A Current Ratio of 3.85 indicates that KNSA has no problem at all paying its short term obligations.
The Current ratio of KNSA (3.85) is comparable to the rest of the industry.
A Quick Ratio of 3.51 indicates that KNSA has no problem at all paying its short term obligations.
KNSA has a Quick ratio (3.51) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.85 | ||
| Quick Ratio | 3.51 |
3. Growth
3.1 Past
KNSA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 421.43%, which is quite impressive.
KNSA shows a strong growth in Revenue. In the last year, the Revenue has grown by 55.68%.
The Revenue has been growing by 122.27% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)421.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%227.78%
Revenue 1Y (TTM)55.68%
Revenue growth 3Y122.27%
Revenue growth 5YN/A
Sales Q2Q%61.17%
3.2 Future
Based on estimates for the next years, KNSA will show a very strong growth in Earnings Per Share. The EPS will grow by 46.94% on average per year.
The Revenue is expected to grow by 24.42% on average over the next years. This is a very strong growth
EPS Next Y273.5%
EPS Next 2Y119.78%
EPS Next 3Y78.67%
EPS Next 5Y46.94%
Revenue Next Year59.08%
Revenue Next 2Y43.77%
Revenue Next 3Y33.48%
Revenue Next 5Y24.42%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 92.40, the valuation of KNSA can be described as expensive.
Based on the Price/Earnings ratio, KNSA is valued cheaply inside the industry as 89.68% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 25.45, KNSA is valued quite expensively.
The Price/Forward Earnings ratio is 24.08, which indicates a rather expensive current valuation of KNSA.
Based on the Price/Forward Earnings ratio, KNSA is valued cheaper than 91.74% of the companies in the same industry.
KNSA's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 34.46.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 92.4 | ||
| Fwd PE | 24.08 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of KNSA indicates a rather cheap valuation: KNSA is cheaper than 90.43% of the companies listed in the same industry.
KNSA's Price/Free Cash Flow ratio is rather cheap when compared to the industry. KNSA is cheaper than 93.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 30.29 | ||
| EV/EBITDA | 64.21 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of KNSA may justify a higher PE ratio.
A more expensive valuation may be justified as KNSA's earnings are expected to grow with 78.67% in the coming years.
PEG (NY)0.34
PEG (5Y)N/A
EPS Next 2Y119.78%
EPS Next 3Y78.67%
5. Dividend
5.1 Amount
No dividends for KNSA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
41.58
+0.09 (+0.22%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners93%
Inst Owner Change-49.77%
Ins Owners3.79%
Ins Owner Change-48.88%
Market Cap3.08B
Revenue(TTM)597.97M
Net Income(TTM)35.92M
Analysts86.15
Price Target55.08 (32.47%)
Short Float %6.76%
Short Ratio6.28
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.24%
Min EPS beat(2)-30.25%
Max EPS beat(2)23.78%
EPS beat(4)2
Avg EPS beat(4)-1408.01%
Min EPS beat(4)-5782.35%
Max EPS beat(4)156.77%
EPS beat(8)4
Avg EPS beat(8)-745.86%
EPS beat(12)7
Avg EPS beat(12)-468.4%
EPS beat(16)10
Avg EPS beat(16)-331.07%
Revenue beat(2)2
Avg Revenue beat(2)5.46%
Min Revenue beat(2)4.99%
Max Revenue beat(2)5.94%
Revenue beat(4)3
Avg Revenue beat(4)2.96%
Min Revenue beat(4)-2.63%
Max Revenue beat(4)5.94%
Revenue beat(8)5
Avg Revenue beat(8)4.2%
Revenue beat(12)9
Avg Revenue beat(12)8.84%
Revenue beat(16)11
Avg Revenue beat(16)8.11%
PT rev (1m)9.4%
PT rev (3m)10.86%
EPS NQ rev (1m)125.2%
EPS NQ rev (3m)125.2%
EPS NY rev (1m)144.71%
EPS NY rev (3m)43.11%
Revenue NQ rev (1m)21.55%
Revenue NQ rev (3m)10.66%
Revenue NY rev (1m)18.53%
Revenue NY rev (3m)18.53%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 92.4 | ||
| Fwd PE | 24.08 | ||
| P/S | 5.15 | ||
| P/FCF | 30.29 | ||
| P/OCF | 29.96 | ||
| P/B | 5.76 | ||
| P/tB | 5.93 | ||
| EV/EBITDA | 64.21 |
EPS(TTM)0.45
EY1.08%
EPS(NY)1.73
Fwd EY4.15%
FCF(TTM)1.37
FCFY3.3%
OCF(TTM)1.39
OCFY3.34%
SpS8.07
BVpS7.22
TBVpS7.02
PEG (NY)0.34
PEG (5Y)N/A
Graham Number8.55
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.04% | ||
| ROE | 6.71% | ||
| ROCE | 6.48% | ||
| ROIC | 5.12% | ||
| ROICexc | 12.74% | ||
| ROICexgc | 13.63% | ||
| OM | 6.38% | ||
| PM (TTM) | 6.01% | ||
| GM | 87.52% | ||
| FCFM | 17.01% |
ROA(3y)11.71%
ROA(5y)-15.78%
ROE(3y)13.22%
ROE(5y)-19.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.87%
GM growth 5YN/A
F-Score8
Asset Turnover0.84
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 75.86% | ||
| Cap/Sales | 0.19% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 259.48% | ||
| Profit Quality | 283.24% | ||
| Current Ratio | 3.85 | ||
| Quick Ratio | 3.51 | ||
| Altman-Z | 11.1 |
F-Score8
WACC9.33%
ROIC/WACC0.55
Cap/Depr(3y)8.83%
Cap/Depr(5y)180.67%
Cap/Sales(3y)0.05%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)421.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%227.78%
EPS Next Y273.5%
EPS Next 2Y119.78%
EPS Next 3Y78.67%
EPS Next 5Y46.94%
Revenue 1Y (TTM)55.68%
Revenue growth 3Y122.27%
Revenue growth 5YN/A
Sales Q2Q%61.17%
Revenue Next Year59.08%
Revenue Next 2Y43.77%
Revenue Next 3Y33.48%
Revenue Next 5Y24.42%
EBIT growth 1Y245.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year468.49%
EBIT Next 3Y113.04%
EBIT Next 5YN/A
FCF growth 1Y3968.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4071.47%
OCF growth 3YN/A
OCF growth 5YN/A
KINIKSA PHARMACEUTICALS INTE / KNSA FAQ
Can you provide the ChartMill fundamental rating for KINIKSA PHARMACEUTICALS INTE?
ChartMill assigns a fundamental rating of 6 / 10 to KNSA.
What is the valuation status for KNSA stock?
ChartMill assigns a valuation rating of 7 / 10 to KINIKSA PHARMACEUTICALS INTE (KNSA). This can be considered as Undervalued.
Can you provide the profitability details for KINIKSA PHARMACEUTICALS INTE?
KINIKSA PHARMACEUTICALS INTE (KNSA) has a profitability rating of 6 / 10.
What are the PE and PB ratios of KINIKSA PHARMACEUTICALS INTE (KNSA) stock?
The Price/Earnings (PE) ratio for KINIKSA PHARMACEUTICALS INTE (KNSA) is 92.4 and the Price/Book (PB) ratio is 5.76.
How financially healthy is KINIKSA PHARMACEUTICALS INTE?
The financial health rating of KINIKSA PHARMACEUTICALS INTE (KNSA) is 7 / 10.